Journal of Clinical and Investigative Surgery
ISSN: 2559-5555
Home » Publications » Volume 7 (2022) » issue 2 » id.17

Rectal GIST mimicking an ovarian mass; a case report

Khaldi Oumeima1,2*, Ghalleb Montassar1,2, Rajhi Slim1,2, Slimane Maher1,2, Doghri Raoudha2,3, Sahraoui Ghada2,3, Chargui Riadh1,2, Khaled Rahal1,2

1 SALAH AZAIEZ INSTITUTE, DEPARTMENT OF SURGICAL ONCOLOGY, TUNIS, TUNISIA

2 FACULTY OF MEDICINE TUNIS EL MANAR, TUNIS, TUNISIA

3 SALAH AZAIEZ INSTITUTE, DEPARTMENT OF PATHOLOGY, TUNIS, TUNISIA

J. Clin. Invest. Surg. 2022; 7(2): Article 17. DOI: 10.25083/2559.5555/7.2.17

Running title: Rectal GIST mimicking an ovarian mass

Keywords: gastrointestinal stromal tumors, GISTs, rectal GIST, ovarian mass, carcinomatosis

Figures: 7; Tables: 1; References: 36

Abstract

Introduction. Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal neoplasms of the gastrointestinal (GI) tract. However, rectal GISTs are rare among these tumors. Case Presentation. A 60-year-old Caucasian woman had surgery for an ovarian mass with carcinomatosis. The patient underwent exploratory laparoscopy, which found a large amount of ascites, epiploic and appendicular carcinomatosis. The Hudson operation was performed to completely and en bloc remove the recto-sigmoid junction, the uterus, and adnexa. The appendix and the carcinomatosis were also removed with no residual tumor. After that, she was sent to the oncology department to start Imatinib therapy. Conclusion. Rectal GIST is a rare entity with varied clinical manifestations and a high risk of recurrence, which may complicate the diagnosis in women with an abdominopelvic tumor mass. Consequently, even if GIST can mimic gynecological tumors, such as ovarian tumor, the surgeon must be aware of this condition and take it into account in establishing the differential diagnosis, especially since surgical treatment is essential in localized rectal GIST.

1. Introduction

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, with an incidence of 10–15 per million per year [1-3]. Most of them originate from the stomach (50–60%), followed by the small intestine (20–30%), the rectum (5%), and the colon 1% [4-6].

Rectal gist can mimic an ovarian mass, which in some cases can lead to a differential diagnosis dilemma for the physician. Our aim is to discuss from this case report the differential diagnosis when faced with a pelvic mass in the post-menopausal woman.

Case presentation

We report the case of a 60-year-old Caucasian woman with no past medical history who was referred to our department for abdominal pain associated with a left abdominopelvic mass. Her blood pressure was 13/7 mm/Hg, and she had a normal heart rate. The body temperature was 370 Celsius. On physical examination, a 15 cm left- abdominal mass was found associated with a mass of the Douglas pouch with reduced mobility.

Ultrasonography showed a 16.5 cm large solid pelvic mass with a cystic component extended to the abdominal cavity, with abundant ascites. Thoraco-abdomino-pelvic computed tomography (CT) showed a 17 cm large solid mass of probable ovarian origin, with cystic component adherent to the posterior surface of the uterus and peritoneal carcinomatosis. No other sign of malignant disease was found on CT (Figures 1-3).

Laboratory findings showed an increase in CA-125 (776,80 U/mL) and normal CA-19.9 and CEA.

The multidisciplinary team decided to start with upfront surgery. The patient had exploratory laparoscopy, which found a-3L- ascites, epiploic and appendicular carcinomatosis. The pelvis was completely filled by a 17 cm mass apparently arising from the ovaries. The mass was adherent to the sigmoid colon, the ovaries, the posterior wall of the uterus, and the peritoneum covering the bladder. The mass was already ruptured and clogged by the ileum and the omentum. Therefore, we decided to carry on a midline laparotomy. Hudson surgery was undertaken to remove completely and on bloc the recto-sigmoid junction, the uterus, and adnexa. The appendix and the carcinomatosis were also removed with no residual tumor. Surgery took three hours and twenty minutes and the patient was transfused with four red blood cell bags. The immediate follow up was without complications.

After the first postoperative day, the patient was mobilized. On the third day, she returned to normal bowel function and received a clear liquid diet. The next day she started a regular diet. She was finally discharged home after five days. She was admitted after ten days for stercoral peritonitis by anastomotic leakage. She had a Hartman procedure and was discharged after five days.

Histopathology was concordant with a 17cm- high risk-colorectal GIST invading the myometrium, the cervix, the peritoneum covering the bladder, and adnexa. Immunohistochemical staining was positive for CD34 and CD117(C-KIT) (Figures 4-7).

Adjuvant treatment by Imatinib was planned with three months follow-up, the patient being well and disease-free. The reverse Hartman will be scheduled in 6 months.

CT scan axial section
Figure 1. CT scan axial section
Ovarian solid mass with cystic component on CT scan axial section
Figure 2. Ovarian solid mass with cystic component on CT scan axial section
Ovarian mass adherent to the posterior surface of the uterus on CT scan axial section
Figure 3. Ovarian mass adherent to the posterior surface of the uterus on CT scan axial section
The tumor invaded the ovary (x 100)
Figure 4. The tumor invaded the ovary (x 100)
Tumor centered in the rectal subserosa (x 100)
Figure 5. Tumor centered in the rectal subserosa (x 100)
CD34 immunostaining (x200)
Figure 6. CD34 immunostaining (x200)
CKIT immunostaining (x 200)
Figure 7. CKIT immunostaining (x 200)

2. Discussion

GISTs are rare tumors and may present a diagnostic dilemma in women with abdominopelvic mass. It is typically present in adults over 50 years. They could present a pelvic mass and lead to misdiagnosis with gynecologic tumors [7-9].

GISTs arise from the interstitial cells of Cajal, which can be found in the myenteric and submucosal plexus of the GI tract [10-12].

The most common presentations of GISTs include gastrointestinal bleeding followed by abdominal pain and bowel obstruction. Other presenting symptoms are abdominal distention, palpable mass, and features of perforation. Abdominal pain and/or GI bleeding are seen more often in large GISTs owing to the vascular nature of the tumor [13-15].

In addition to the nonspecific clinical presentation, no characteristic biochemical markers or typical imaging features of GIST have been demonstrated. Thus, a contrast-enhanced CT scan should be performed to determine the extent of the tumor and the presence or absence of metastatic disease, as well as the possibility of complete resection. Diagnosis is established based on histopathology and immunophenotyping. CD117 (C-kit) and DOG-1 have the most diagnostic value with high sensitivity (94%) [16]. In our case, the diagnosis was confirmed through C-Kit.

Pelvic mass in a post-menopausal woman is a common disorder that represents a spectrum of conditions with many causes. A mass may be gynecologic, digestive, or ureteral. Concerning gynecological masses, they are commonly ovarian but may also arise from the uterus or fallopian tube. The main etiologies have been summarized in Table 1 [17-19].

gynecologic ureteral digestive others benign malignant *Bladder diverticulum *Diverticular abscess *Pelvic kidney

*Gastrointestinal carcinoma *Krukenberg tumor *Sigmoidite

*aneurysm *Retroperitoneal sarcoma *Mature teratoma *Ovarian torsion *Serous/mucinous cystadenoma *Endometrioma *Hydrosalpinx *Leiomyoma *Tubo ovarian abscess

*Borderline tumor *Epithelial carcinoma *Ovarian germ cell tumor

*Sex cord tumor *Endometrial carcinoma *Fallopian tube carcinoma Clinical history and examination are crucial to determine the possible causes. Pain is a common symptom. Obstructive symptoms such as urinary, bowel dysfunction, or even lower limb venous thromboembolism are frequent symptoms. Uterine masses can be associated with symptoms of vaginal bleeding or dyspareunia and dysmenorrhea. Clinical abdominal examination may reveal a palpable mass or demonstrate ascites in the cases of ovarian cancer.

The standard treatment of localized GIST is surgical with negative margins without lymph node resection. During surgery, it is important to guarantee complete tumor resection and avoid tumor rupture.

The surgical treatment of rectal GISTs can be grouped into two categories: local resection and radical excision. The former includes trans-anal endoscopic microsurgery (TEM) and trans-anal minimally invasive surgery (TAMIS), while the latter includes low anterior resection and abdominoperineal resection (APR), and pelvic exenteration [20-22].

Large and aggressive rectal GISTs with extensive extra-rectal growth— invading adjacent structures, such as the prostate, vagina, or sacrum, usually require a more extensive resection [23,24].

The most significant factor related to outcome is complete resection, and this can be accomplished in 40- 60% of all GIST patients [25,26]. Rectal GISTs have a high rate of local recurrence regardless of the surgical procedure. That’s why adjuvant medical therapy has gained importance in the management of colorectal GIST. Beyond minimizing disease recurrence, adjuvant therapy can also be useful in case of intraoperative tumor rupture and incomplete tumor removal.

Imatinib, a specific tyrosine kinase receptor inhibitor (TKI), is the only available and approved therapy as the first-line treatment for advanced GIST [27-29].

The colorectal GISTs usually metastasize to the liver, peritoneum, and sometimes to the lung and bone. Imatinib is the first-line treatment for advanced disease for patients with sensitive mutations to TKI, which should be continued for an unlimited period of time according to the ESMO [30,31].

The prognosis of the tumor depends on the age at presentation, anatomic location, size, immuno-histo-chemistry, molecular genetics, and mitotic activity [32,33].

Recurrence of GIST is a common complication despite full resection with negative margins. That’s why regular follow-up examinations and investigations are compulsory. The NCCN guidelines suggest physical examination and abdominopelvic CT scan every 3 to 6 months in the first 3 to 5 years after surgery and annually thereafter [34-36].

Table 1. The main etiologies of pelvic mass in a post-menopausal woman

Table 1. The main etiologies of pelvic mass in a post-menopausal woman
gynecologicureteraldigestiveothers
benignmalignant*Bladder diverticulum *Diverticular abscess *Pelvic kidney*Gastrointestinal carcinoma *Krukenberg tumor *Sigmoidite*aneurysm *Retroperitoneal sarcoma
*Mature teratoma *Ovarian torsion *Serous/mucinous cystadenoma *Endometrioma *Hydrosalpinx *Leiomyoma *Tubo ovarian abscess*Borderline tumor *Epithelial carcinoma *Ovarian germ cell tumor *Sex cord tumor *Endometrial carcinoma *Fallopian tube carcinoma

3. Conclusions

Rectal GIST is a rare tumor with malignant potential and a high risk of recurrence, which poses a diagnostic dilemma in women with abdominopelvic mass. As it may mimic gynecologic tumors like an ovarian tumor, the surgeon should be aware of this condition and consider it in the differential diagnosis. Authors’ contribution

MG, OK, SR: data collection, drafted the manuscript MS, RD: review of the literature RC, KR: drafted the manuscript

Institutional Review Board Statement

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

Acknowledgments

AcknowledgmentsThe paramedical team of the surgery department of the Salah Azaiez Institute for their continuous support.

Conflicts of Interest

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Copyright and License

© 2022 by the authors.

open-access — This is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

References

  1. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. Feb;40:39-46. doi: 10.1016/j.canep.2015.10.031
  2. Li Y, Zhang Y, Fu Y, Yang W, Wang X, Duan L, Niu L, Chen J, Zhou W, Liu J, Wang J, Fan D, Hong L. Development and validation of a prognostic model to predict the prognosis of patients with colorectal gastrointestinal stromal tumor: A large international population-based cohort study. Front Oncol. 2022 Nov 2;12:1004662. doi: 10.3389/fonc.2022.1004662
  3. Yu X, Liang X, Wen K. Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review). Oncol Lett. 2022 Nov 1; 24(6):453. doi: 10.3892/ol.2022.13573
  4. Landi B, Bouché O, Guimbaud R, Chayvialle JA. Tumeurs stromales gastro-intestinales (GIST) de taille limitée (inférieure à 5cm): revue de la littérature et propositions pour la prise en charge [Gastrointestinal stromal tumors (GIST)<5 cm in size: review of the literature and expert propositions for clinical management]. Gastroenterol Clin Biol. 2010 Feb; 34(2):120-33. doi: 10.1016/j.gcb.2009.06.019
  5. Wu J, Zhuang M, Zhou Y, Zhan X, Xie W. The value of contrast-enhanced harmonic endoscopic ultrasound in differential diagnosis and evaluation of malignant risk of gastrointestinal stromal tumors (<50mm). Scand J Gastroenterol. 2022 Nov 11:1-7. doi: 10.1080/00365521.2022.2144437
  6. Weeda YA, Kalisvaart GM, Velden FHPV, Gelderblom H, Molen AJV, Bovee JVMG, Hage JAV, Grootjans W, Geus-Oei LF. Early Prediction and Monitoring of Treatment Response in Gastrointestinal Stromal Tumors by Means of Imaging: A Systematic Review. Diagnostics (Basel). 2022 Nov 7;12(11):2722. doi: 10.3390/diagnostics12112722
  7. Tao K, Zeng X, Liu W, Wang S, Gao J, Shuai X, Zhang P. Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis. J Surg Res. 2020 Feb;246:584-590. doi: 10.1016/j.jss.2019.09.043
  8. Li C, Lu Y, Zhang MM, Wu H, Li H, Ye YJ, Jiang K. Clinicopathological features and prognosis of colonic and rectal gastrointestinal stromal tumors: A propensity score matching analysis. Front Surg. 2022 Oct 21;9: 968585. doi: 10.3389/fsurg.2022.968585
  9. Ge QC, Wu YF, Liu ZM, Wang Z, Wang S, Liu X, Ge N, Guo JT, Sun SY. Efficacy of endoscopic ultrasound in the evaluation of small gastrointestinal stromal tumors. World J Gastroenterol. 2022 Oct 7;28(37): 5457-5468. doi: 10.3748/wjg.v28.i37.5457
  10. Alfagih A, AlJassim A, Alshamsan B, Alqahtani N, Asmis T. Gastrointestinal Stromal Tumors: 10-Year Experience in Cancer Center-The Ottawa Hospital (TOH). Curr Oncol. 2022 Sep 29;29(10):7148-7157. doi: 10.3390/curroncol29100562
  11. Lin SC, Yen HH, Lee PC, Lai IR. Oncological outcomes of large gastrointestinal stromal tumors treated by laparoscopic resection. Surg Endosc. 2022 Oct 25. doi: 10.1007/s00464-022-09693-x
  12. Dumitriu B, Valcea S, Andrei G, Beuran M. Evaluation of anemia as a postoperative risk factor in the evolution of patients with gastric resection for malignancies. J Clin Investig Surg. 2021 Nov 25;6(2):136-140. doi: 10.25083/2559.5555/6.2.8
  13. Marcella C, Shi RH, Sarwar S. Clinical Overview of GIST and Its Latest Management by Endoscopic Resection in Upper GI: A Literature Review. Gastroenterol Res Pract. 2018 Oct 31;2018:6864256. doi: 10.1155/2018/6864256
  14. Hu X, Zhang Q, Wang Z, Ren H, Su P, Kou Y. Retrospective study of the clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients. Ann Diagn Pathol. 2022 Oct 14;61:152050. doi: 10.1016/j.anndiagpath.2022.152050
  15. Khachatryan V, Muazzam A, Hamal C, Velugoti LSDR, Tabowei G, Gaddipati GN, Mukhtar M, Alzubaidee MJ, Dwarampudi RS, Mathew S, Bichenapally S, Mohammed L. The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review. Cureus. 2022 Sep 1;14(9):e28665. doi: 10.7759/cureus.28665
  16. Rahma DY, Atmaja MHS. Gastrointestinal stromal tumor as mimicking gynecological mass finding on CT scan imaging: A case report. Int J Surg Case Rep. 2022 May;94:107092. doi: 10.1016/j.ijscr.2022.107092
  17. Ijeri SK, Rathod PS, Kundargi R, Pallavi VR, Shobha K, Shankaranand, Vijay CR, Uma Devi K, Bafna UD. Gastrointestinal Stromal Tumor Mimicking as Ovarian Tumor in Gynaecologic Oncology. Indian J Surg Oncol. 2016 Mar;7(1):56-61. doi: 10.1007/s13193- 015-0479-8
  18. Davila RE. A Gastroenterologist's Approach to the Diagnosis and Management of Gastrointestinal Stromal Tumors. Gastroenterol Clin North Am. 2022 Sep;51(3): 609-624. doi: 10.1016/j.gtc.2022.06.009
  19. Dumitriu B, Valcea S, Andrei G, Beuran M. The impact of patient-dependent risk factors on morbidity and mortality following gastric surgery for malignancies. J Mind Med Sci. 2021;8(2):267-272. doi: 10.22543/7674.82.P267272
  20. Reis NRP, Barbosa LER. Prognostic Factors and Management of Colorectal Gastrointestinal Stromal Tumors. J Coloproctology. 2022 Mar 1;42(1):68–76. doi: 10.1055/s-0041-1740297
  21. Emile SH, Horesh N, Freund MR, Garoufalia Z, Gefen R, Silva-Alvarenga E, Wexner SD. Outcomes of Local Excision Compared to Radical Excision of Rectal Gastrointestinal Stromal Tumors: A Propensity-Score Matched Analysis of the NCDB. World J Surg. 2022 Oct 11. doi: 10.1007/s00268-022-06778-5
  22. Uzun O, Senger AS, Gülmez S, Ömeroğlu S, Ofluoğlu BC, Öz A, Polat E, Duman M. Evaluating the effect of tumor size on survival and its prognostic significance among gastric cancer patients. J Clin Investig Surg. 2020;5(2):76-82. doi: 10.25083/2559.5555/5.2/76.82
  23. Yue L, Sun Y, Hu M, Hu W. Might Patients with Metastatic Gastrointestinal Stromal Tumors Benefit from Operative Management? A Population-Based Retrospective Study. Biomed Res Int. 2022 Sep 7;2022:9432410. doi: 10.1155/2022/9432410
  24. Jabłońska B, Szmigiel P, Wosiewicz P, Baron J, Szczęsny-Karczewska W, Mrowiec S. A jejunal gastrointestinal stromal tumor with massive gastrointestinal hemorrhage treated by emergency surgery: A case report. Medicine (Baltimore). 2022 Sep 2;101(35):e30098. doi: 10.1097/MD.0000000000030098
  25. Wei J, Zhong J, Chen Z, Huang Q, Wei F, Wang Q, Cao J. Survival outcome of local vs. radical excision in rectal gastrointestinal stromal tumor: a SEER database analysis. BMC Surg. 2022 Jan 22;22(1):21. doi: 10.1186/s12893-022-01485-3
  26. Alius C, Cirstoveanu CG, Badiu CD, Ardeleanu V, Dumitru VA. Immunohistochemical pattern– a prognostic factor for synchronous gastrointestinal cancer. J Mind Med Sci. 2020;7(2):250-256. doi: 10.22543/7674.72.P250256
  27. Farid M, Ong J, Chia C, Tan G, Teo M, Quek R, Teh J, Matchar D. Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis. Clin Sarcoma Res. 2020 Aug 6;10:13. doi: 10.1186/s13569-020-00135-7
  28. Li W, Li X, Yu K, Xiao B, Peng J, Zhang R, Zhang L, Wang K, Pan Z, Li C, Wu X. Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study. Front Pharmacol. 2022 Sep 27;13:950101. doi: 10.3389/fphar.2022.950101
  29. Wu T, Cheng X, Chen W. Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review. Medicine (Baltimore). 2022 Aug 12;101(32):e29411. doi: 10.1097/MD.0000000000029411
  30. Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, et al; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005
  31. Bang YH, Ryu MH, Kim HD, Lee HE, Kang YK. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib. Int J Cancer. 2022 Nov 15;151(10):1770-1777. doi: 10.1002/ijc.34157
  32. Huang PH, Chen YY, Chen HH, Ting WH, Lin HH, Chen KH, Hsiao SM. Factors affecting clinical outcomes in women with non-gastric gastrointestinal stromal tumors. Taiwan J Obstet Gynecol. 2022 Mar; 61(2):306-311. doi: 10.1016/j.tjog.2022.02.019
  33. Pantaleo MA, Heinrich MC, Italiano A, Valverde C, Schöffski P, Grignani G, Reyners AKL, Bauer S, Reichardt P, Stark D, Berhanu G, Brandt U, Stefanelli T, Gelderblom H. A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. BMC Cancer. 2022 May 6;22(1):511. doi: 10.1186/s12885-022-09610-4
  34. Zhao WY, Zhao G, Wang M. [Updates and interpretations of the NCCN Clinical Practice Guidelines (2019 6th version) on gastrointestinal stromal tumor]. Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23(9):866-871. doi: 10.3760/cma.j.cn.441530- 20200731-00454
  35. Chen XS, Yuan W, Xu ZH, Yang YT, Dong SY, Liu LH, Zeng MS, Hou YY, Rao SX. Prognostic value of preoperative CT features for disease-free survival in patients with primary gastric gastrointestinal stromal tumors after resection. Abdom Radiol (NY). 2022 Nov 11. doi: 10.1007/s00261-022-03725-9
  36. Albano D, Mattia B, Giubbini R, Bertagna F. Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST. Abdom Radiol (NY). 2020 Mar;45(3):644-651. doi: 10.1007/s00261-019-02274-y
Institutional e-repository
Copyright © 2016–2026. All rights reserved.